Suppr超能文献

无症状 SARS-CoV-2 感染的比例:系统评价。

The Proportion of SARS-CoV-2 Infections That Are Asymptomatic : A Systematic Review.

机构信息

Scripps Research Translational Institute, La Jolla, California (D.P.O., E.J.T.).

出版信息

Ann Intern Med. 2021 May;174(5):655-662. doi: 10.7326/M20-6976. Epub 2021 Jan 22.

Abstract

BACKGROUND

Asymptomatic infection seems to be a notable feature of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen that causes coronavirus disease 2019 (COVID-19), but the prevalence is uncertain.

PURPOSE

To estimate the proportion of persons infected with SARS-CoV-2 who never develop symptoms.

DATA SOURCES

Searches of Google News, Google Scholar, medRxiv, and PubMed using the keywords , , , , , , and .

STUDY SELECTION

Observational, descriptive studies and reports of mass screening for SARS-CoV-2 that were either cross-sectional or longitudinal in design; were published through 17 November 2020; and involved SARS-CoV-2 nucleic acid or antibody testing of a target population, regardless of current symptomatic status, over a defined period.

DATA EXTRACTION

The authors collaboratively extracted data on the study design, type of testing performed, number of participants, criteria for determining symptomatic status, testing results, and setting.

DATA SYNTHESIS

Sixty-one eligible studies and reports were identified, of which 43 used polymerase chain reaction (PCR) testing of nasopharyngeal swabs to detect current SARS-CoV-2 infection and 18 used antibody testing to detect current or prior infection. In the 14 studies with longitudinal data that reported information on the evolution of symptomatic status, nearly three quarters of persons who tested positive but had no symptoms at the time of testing remained asymptomatic. The highest-quality evidence comes from nationwide, representative serosurveys of England ( = 365 104) and Spain ( = 61 075), which suggest that at least one third of SARS-CoV-2 infections are asymptomatic.

LIMITATION

For PCR-based studies, data are limited to distinguish presymptomatic from asymptomatic infection. Heterogeneity precluded formal quantitative syntheses.

CONCLUSION

Available data suggest that at least one third of SARS-CoV-2 infections are asymptomatic. Longitudinal studies suggest that nearly three quarters of persons who receive a positive PCR test result but have no symptoms at the time of testing will remain asymptomatic. Control strategies for COVID-19 should be altered, taking into account the prevalence and transmission risk of asymptomatic SARS-CoV-2 infection.

PRIMARY FUNDING SOURCE

National Institutes of Health.

摘要

背景

无症状感染似乎是严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的一个显著特征,SARS-CoV-2 是导致 2019 冠状病毒病(COVID-19)的病原体,但流行情况尚不确定。

目的

估计感染 SARS-CoV-2 但从未出现症状的人群比例。

数据来源

使用关键词“coronavirus,”“COVID-19,”“SARS-CoV-2,”“asymptomatic infection,”“seroprevalence,”“PCR,”和“antibody”,在 Google News、Google Scholar、medRxiv 和 PubMed 上进行搜索。

研究选择

观察性、描述性研究以及 SARS-CoV-2 大规模筛查的报告,研究设计为横断面或纵向;通过 2020 年 11 月 17 日之前发表;并涉及 SARS-CoV-2 核酸或抗体检测,检测对象为目标人群,无论当前的症状状态如何,在定义的时间段内进行。

数据提取

作者合作提取了研究设计、进行的检测类型、参与者数量、确定症状状态的标准、检测结果和研究地点等数据。

数据综合

确定了 61 项符合条件的研究和报告,其中 43 项使用聚合酶链反应(PCR)检测鼻咽拭子来检测当前的 SARS-CoV-2 感染,18 项使用抗体检测来检测当前或先前的感染。在 14 项具有纵向数据的研究中,报告了症状状态演变的信息,近四分之三在检测时呈阳性但无症状的人仍然无症状。最优质的证据来自英格兰( = 365 104)和西班牙( = 61 075)全国代表性血清学调查,表明至少三分之一的 SARS-CoV-2 感染是无症状的。

局限性

对于基于 PCR 的研究,数据仅限于区分前驱期和无症状感染。异质性排除了正式的定量综合。

结论

现有数据表明,至少三分之一的 SARS-CoV-2 感染是无症状的。纵向研究表明,近四分之三在检测时呈阳性但无症状的人将保持无症状。应改变针对 COVID-19 的控制策略,考虑无症状 SARS-CoV-2 感染的流行率和传播风险。

主要资金来源

美国国立卫生研究院。

相似文献

1
The Proportion of SARS-CoV-2 Infections That Are Asymptomatic : A Systematic Review.
Ann Intern Med. 2021 May;174(5):655-662. doi: 10.7326/M20-6976. Epub 2021 Jan 22.
2
Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis.
PLoS Med. 2020 Sep 22;17(9):e1003346. doi: 10.1371/journal.pmed.1003346. eCollection 2020 Sep.
3
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.
Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3.
5
Universal screening for SARS-CoV-2 infection: a rapid review.
Cochrane Database Syst Rev. 2020 Sep 15;9(9):CD013718. doi: 10.1002/14651858.CD013718.
9

引用本文的文献

2
Assessment of the relationship between hematologic parameters, (CPD), in screening for COVID-19 severity in women.
Future Sci OA. 2025 Dec;11(1):2540749. doi: 10.1080/20565623.2025.2540749. Epub 2025 Aug 2.
3
A comparative analysis of clinical characteristics between primary and recurrent COVID-19 infections in China.
Infect Med (Beijing). 2025 Jun 18;4(3):100187. doi: 10.1016/j.imj.2025.100187. eCollection 2025 Sep.
4
Is Altered Surfactant Protein Gene Expression in Peripheral Blood Associated with COVID-19 Disease Severity?
Diagnostics (Basel). 2025 Jul 2;15(13):1690. doi: 10.3390/diagnostics15131690.
6
Longitudinal SARS-CoV-2 antibody response in a healthcare worker cohort utilising the Abbott Alinity® anti-nucleocapsid assay.
PLoS One. 2025 Jun 11;20(6):e0325544. doi: 10.1371/journal.pone.0325544. eCollection 2025.
7
The impacts of gradually terminating nonpharmaceutical interventions for SARS-CoV-2: A mathematical modelling analysis.
Fundam Res. 2022 May 17;4(2):401-411. doi: 10.1016/j.fmre.2022.05.007. eCollection 2024 Mar.
9
Post-exposure testing at healthcare facilities with SARS-CoV-2 transmission: A rapid review.
J Public Health Afr. 2025 Feb 23;16(2):623. doi: 10.4102/jphia.v16i2.623. eCollection 2025.
10
Autoantibodies in COVID-19: implications for disease severity and clinical outcomes.
Front Immunol. 2025 Jan 6;15:1509289. doi: 10.3389/fimmu.2024.1509289. eCollection 2024.

本文引用的文献

1
The Association of "Loss of Smell" to COVID-19: A Systematic Review and Meta-Analysis.
Am J Med Sci. 2021 Feb;361(2):216-225. doi: 10.1016/j.amjms.2020.09.017. Epub 2020 Nov 1.
2
Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection.
Front Immunol. 2020 Nov 30;11:611337. doi: 10.3389/fimmu.2020.611337. eCollection 2020.
3
COVID-19 Vaccines May Not Prevent Nasal SARS-CoV-2 Infection and Asymptomatic Transmission.
Otolaryngol Head Neck Surg. 2021 Feb;164(2):305-307. doi: 10.1177/0194599820982633. Epub 2020 Dec 15.
5
Effective control of SARS-CoV-2 transmission in Wanzhou, China.
Nat Med. 2021 Jan;27(1):86-93. doi: 10.1038/s41591-020-01178-5. Epub 2020 Nov 30.
7
Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19.
J Allergy Clin Immunol. 2021 Feb;147(2):545-557.e9. doi: 10.1016/j.jaci.2020.10.040. Epub 2020 Nov 20.
9
Pattern of SARS-CoV-2 infection among dependant elderly residents living in long-term care facilities in Marseille, France, March-June 2020.
Int J Antimicrob Agents. 2020 Dec;56(6):106219. doi: 10.1016/j.ijantimicag.2020.106219. Epub 2020 Nov 13.
10
SARS-CoV-2 Transmission among Marine Recruits during Quarantine.
N Engl J Med. 2020 Dec 17;383(25):2407-2416. doi: 10.1056/NEJMoa2029717. Epub 2020 Nov 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验